ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Characterization of lung adenocarcinoma based on immunophenotyping and constructing an immune scoring model to predict prognosis

Liu, Mengfeng; Xiao, Qifan; Yu, Xiran; Zhao, Yujie; Qu, Changfa*哈尔滨医科大学
Frontiers in Pharmacology2022-12-19DOI: 10.3389/fphar.2022.1081244
5阅读
引用收藏
分享

摘要

Background: Lung cancer poses great threat to human health, and lung adenocarcinoma (LUAD) is the main subtype. Immunotherapy has become first line therapy for LUAD. However, the pathogenic mechanism of LUAD is still unclear. Methods: We scored immune-related pathways in LUAD patients using single sample gene set enrichment analysis (ssGSEA) algorithm, and further identified distinct immune-related subtypes through consistent clustering analysis. Next, immune signatures, Kaplan-Meier survival analysis, copy number variation (CNV) analysis, gene methylation analysis, mutational analysis were used to reveal differences between subtypes. pRRophetic method was used to predict the response to chemotherapeutic drugs (half maximal inhibitory concentration). Then, weighted gene co-expression network analysis (WGCNA) was performed to screen hub genes. Significantly, we built an immune score (IMscore) model to predict prognosis of LUAD. Results: Consensus clustering analysis identified three LUAD subtypes, namely immune-Enrich subtype (Immune-E), stromal-Enrich subtype (Stromal-E) and immune-Deprived subtype (Immune-D). Stromal-E subtype had a better prognosis, as shown by Kaplan-Meier survival analysis. Higher tumor purity and lower immune cell scores were found in the Immune-D subtype. CNV analysis showed that homologous recombination deficiency was lower in Stromal-E and higher in Immune-D. Likewise, mutational analysis found that the Stromal-E subtype had a lower mutation frequency in TP53 mutations. Difference in gene methylation (ZEB2, TWIST1, CDH2, CDH1 and CLDN1) among three subtypes was also observed. Moreover, Immune-E was more sensitive to traditional chemotherapy drugs Cisplatin, Sunitinib, Crizotinib, Dasatinib, Bortezomib, and Midostaurin in both the TCGA and GSE cohorts. Furthermore, a 6-gene signature was constructed to predicting prognosis, which performed better than TIDE score. The performance of IMscore model was successfully validated in three independent datasets and pan-cancer.

学科与关键词

关键词
LUADimmuneimmunophenotypingimmune scoring modelprognosis
相关
加载中…
  • DNA methylation-based lung adenocarcinoma subtypes can predict prognosis, recurrence, and immunotherapeutic implications
    Xu, Feng; He, Lulu; Zhan, Xueqin; Chen, Jiexin; Xu, Huan; Huang, Xiaoling; Li, Yangyi; Zheng, Xiaohe; Lin, Ling*; Chen, Yongsong*Aging-US, 2020, 12(24): 25275-25293.被引 3
  • Immunogenic cell death-based prognostic model for predicting the response to immunotherapy and common therapy in lung adenocarcinoma
    Zhou, Xiang; Xu, Ran; Lu, Tong; Wang, Chenghao; Chang, Xiaoyan; Peng, Bo; Shen, Zhiping; Yao, Lingqi; Wang, Kaiyu; Xu, Chengyu; Shi, Jiaxin; Zhang, Ren; Zhao, Jiaying; Zhang, Linyou*Scientific Reports, 2023, 13(1).
  • Molecular characterization based on tumor microenvironment-related signatures for guiding immunotherapy and therapeutic resistance in lung adenocarcinoma
    Jie, Yamin; Wu, Jianing; An, Dongxue; Li, Man; He, Hongjiang; Wang, Duo; Gu, Anxin*; Mingyan, E.*Frontiers in Pharmacology, 2023, 14: 1099927.被引 1
查看全部 →

发表信息

论文状态
公开发表
期刊
Frontiers in Pharmacology
发表日期
2022-12-19
卷期
第 13 卷
页码
1081244
DOI
10.3389/fphar.2022.1081244
语言
ENGLISH
期刊等级
2区
成果收录
SCIE

作者

  • L

    Liu, Mengfeng (第一作者)

    harbin med univ

  • X

    Xiao, Qifan

    harbin med univ

查看全部 5 位作者收起作者
  • Y

    Yu, Xiran

    harbin med univ

  • Z

    Zhao, Yujie

  • Q

    Qu, Changfa (通讯)

    harbin med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417